GLAUKOS Corp
Glaukos (GKOS) filed and posted an investor presentation outlining progress for iDose TR, including FDA re-administration approval in Jan 2026 for up to 3 years of therapy, and the March 2026 launch of Epioxa for keratoconus. It also cites a pipeline of 13 programs and 2026 revenue guidance midpoint of about $690M, with $289M cash and no debt as of 6/30/2026.
H.C. Wainwright raised its Glaukos (NYSE:GKOS) price target to $195 from $168 and kept a Buy rating after Glaukos reported Q2 2026 results. Revenue was $185.6M, up 49.5% YoY, and glaucoma revenue was $155.2M. Glaukos raised full-year 2026 net sales guidance to $680M-$700M.
Simply Wall St reports that Glaukos (GKOS) rose 10.8% after the company raised its 2026 sales guidance and advanced its PRESERFLO study. The piece also references other fair value estimates and notes potential upside and a warning sign, based on historical data and analyst forecasts.
Over the past 7 days, alphai's AI scored 1 news story mentioning GKOS (GLAUKOS Corp). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent GKOS coverage spans financial news, earnings and technology.
In the last 30 days, GKOS insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($3.2M). The most active reporter was Thurman Alex R., SVP & CHIEF FINANCIAL OFFICER, with 2 filings. 67% of activity was filed under pre-arranged Rule 10b5-1 plans.
The disclosure is a forward-looking commercial and pipeline update that can shift near-term expectations for glaucoma/keratoconus revenue and adoption.
Analyst target hike is a near-term sentiment tailwind, anchored to stronger-than-expected revenue and raised 2026 sales guidance.
If the guidance increase and PRESERFLO advancement are accurate, they likely improve forward revenue visibility and clinical/proof-of-concept momentum.
The earnings beat plus guidance raise is a near-term positive catalyst, likely supporting momentum and improving forward expectations for iDose TR and Epioxa commercialization.
Analyst target hike is a near-term sentiment catalyst, but it is not a new company disclosure; the key incremental detail is Truist’s updated segment valuation and J-code confidence.
alphai scores every news story that mentions GKOS with an AI model for sentiment and relevance, and aggregates insider trades from GLAUKOS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Glaukos (GKOS) filed and posted an investor presentation outlining progress for iDose TR, including FDA re-administration approval in Jan 2026 for up to 3 years of therapy, and the March 2026 launch of Epioxa for keratoconus. It also cites a pipeline of 13 programs and 2026 revenue guidance midpoint of about $690M, with $289M cash and no debt as of 6/30/2026.
1 min readH.C. Wainwright raised its Glaukos (NYSE:GKOS) price target to $195 from $168 and kept a Buy rating after Glaukos reported Q2 2026 results. Revenue was $185.6M, up 49.5% YoY, and glaucoma revenue was $155.2M. Glaukos raised full-year 2026 net sales guidance to $680M-$700M.
4 min readSimply Wall St reports that Glaukos (GKOS) rose 10.8% after the company raised its 2026 sales guidance and advanced its PRESERFLO study. The piece also references other fair value estimates and notes potential upside and a warning sign, based on historical data and analyst forecasts.
2 min readGlaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.
6 min readTruist Securities raised its price target for Glaukos (NYSE:GKOS) to $215 from $180 and kept a Buy rating. The stock trades at $161.66 near its 52-week high. Truist cited higher estimates, including valuation contributions from iDose and Corneal Health, and noted increased confidence after a J-code secured July 1, 2026. Glaukos reported Q2 2026 results and raised its full-year sales outlook.
2 min readGlaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.
4 min readGLAUKOS Corp (GKOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designe
6 min readA midday roundup highlights multiple movers. V.F. Corp. (VFC) fell 17% to $15.24 after lower first-quarter revenue tied to weakness in Vans and CFO Paul Vogel leaving. Envista (NVST) rose 6.2% to $28.63 ahead of an Sept. 17 investor day. Glaukos (GKOS) gained 7.9% to $159.25 after completing patient enrollment in a 510(k) glaucoma study.
3 min readGlaukos said patient enrolment is complete for its US 510(k) pivotal, prospective multi-centre single-arm trial of the Preserflo MicroShunt in adults with primary open-angle glaucoma. The study reached at least 110 patients. The main endpoint is a 20%+ reduction in mean diurnal IOP at 12 months without adding medication classes. Glaukos plans FDA marketing clearance using trial data.
2 min readGlaukos (NYSE: GKOS) said it completed patient enrollment in a U.S. 510(k) pivotal study of the PRESERFLO MicroShunt for adult primary open-angle glaucoma patients whose IOP was inadequately controlled after prior treatment. The single-arm trial enrolled at least 110 patients. Glaukos plans to use results to support a future FDA marketing submission.
3 min read
